ArticleCureus2026
Edinburgh University Solution of Lime (EUSOL) Versus Platelet-Derived Growth Factor Dressing for Wound Contraction in Grade II Wagner Diabetic Foot Ulcers: A Randomized Controlled Trial.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Diabetic foot ulcers remain a leading cause of lower-limb amputation worldwide, and wound management is especially difficult in resource-limited settings where older antiseptic agents such as Edinburgh University Solution of Lime (EUSOL) are still in routine use. This trial compared EUSOL dressing with platelet-derived growth factor (PDGF) dressing for wound contraction in Grade II Wagner diabetic foot ulcers. Methodology In this randomized controlled trial, 120 patients aged 30 to 70 years with Grade II Wagner diabetic foot ulcers were assigned in a 1:1 ratio to daily EUSOL dressing or PDGF dressing applied every fourth day for four weeks after debridement and infection control. Wound healing was defined as a reduction in ulcer area of at least 50% from baseline at four weeks. A multivariate logistic regression model examined treatment group, age, sex, body mass index (BMI), diabetes duration, and antidiabetic therapy as predictors of healing. Results Patients averaged 49.8 ± 10.2 years of age and a BMI of 27.1 ± 3.45 kg/m²; 58.3% were male. Seventy-eight patients (65%) used oral hypoglycemic agents alone, while 42 (35%) required insulin. Seventy-one patients (59.2%) had diabetes for more than 10 years. Wound contraction occurred in 20 of 60 (33.3%) patients on EUSOL versus 44 of 60 (73.3%) on PDGF (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.